L
L01XX08 Pentostatin
[L01XX] Other antineoplastic agents
[L01X] OTHER ANTINEOPLASTIC AGENTS
[L01] ANTINEOPLASTIC AGENTS
[L] Antineoplastic and immunomodulating agents
Pictogram | Signal | Statements | Precautionary Statement Codes |
---|---|---|---|
Danger |
Aggregated GHS information provided by 39 companies from 2 notifications to the ECHA C&L Inventory. H301 (97.44%): Toxic if swallowed [Danger Acute toxicity, oral] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P264, P270, P301+P310, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) | |
(8R)-3-(2-Deoxy-?-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol | (8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol | (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,4H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol |
(8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H,6H,7H,8H-imidazo[4,5-d][1,3]diazepin-8-ol | (8R)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-7,8-dihydro-6H-imidazo[4,5-d][1,3]diazepin-8-ol | (R)-2'-Deoxycoformycin |
(R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol | (R)-3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo(4,5-d)(1,3)diazepin-8-ol | (R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol |
(R)-Deoxycoformycin | (R,Z)-3-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol | 2'-DCF |
2'-Deoxycoformycin | 2'-Dexoycoformycin | 395575MZO7 |
53910-25-1 | 8R-2'-Deoxycoformycin | 910P251 |
A3708 | AB0010579 | AKOS024456918 |
AKOS032949742 | API0005275 | BDBM223291 |
BDBM22925 | BIDD:GT0136 | BRN 1223097 |
C02267 | CAS-53910-25-1 | CHEMBL1580 |
CI-825 | CL 67310465 | CL-67310465 |
CO-Vidarabine | CS-0374 | Co-V |
Covidarabine | D00155 | DB00552 |
DSSTox_CID_3436 | DSSTox_GSID_23436 | DSSTox_RID_77027 |
DTXSID2023436 | Deaminase inhibitor (PD) | Deaminase, inhibitor for adenosine arabinoside |
Deoxycoformycin | EN300-222177 | FPVKHBSQESCIEP-JQCXWYLXSA-N |
GTPL4805 | HSDB 6547 | HY-A0006 |
Imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)- | Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- | J-523899 |
NCGC00182045-01 | NCGC00388420-02 | NSC 218321 |
NSC-218321 | Nipent | PB12063 |
PD 81565 | PD-81565 | PD-ADI |
Pentostatin (JAN/USAN/INN) | Pentostatin (PTN) | Pentostatin [USAN:INN:BAN:JAN] |
Pentostatin(Deoxycoformycin) | Pentostatin, >=95% (HPLC) | Pentostatina |
Pentostatina [INN-Spanish] | Pentostatine | Pentostatine [INN-French] |
Pentostatinum | Pentostatinum [INN-Latin] | Pentostatn |
Q-4464 | Q425470 | SCHEMBL2817 |
SR-01000883935 | SR-01000883935-1 | Tox21_113417 |
UNII-395575MZO7 | Vidarbine | Vira A deaminase inhibitor |
YK-176 | Z2216208604 | ZINC3806262 |
dCF | pentostatin |
DrugBank Name | Pentostatin |
DrugBank | DB00552 |
CAS Number | 53910-25-1 |
PubChem Compound | 439693 |
KEGG Compound ID | C02267 |
KEGG Drug | D00155 |
PubChem.Substance | 46507116 |
PharmGKB | PA450863 |
ChemSpider | 388759 |
BindingDB | 22925.0 |
TTD | DAP000566 |
Wikipedia | Pentostatin |
HET | DCF |
DPD | 1740 |